Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently,...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 10; no. 1; pp. 439 - 442
Main Authors GÜNALDI, MERAL, AFSAR, CIGDEM USUL, DUMAN, BERNA BOZKURT, KARA, ISMAIL OGUZ, TATLI, UFUK, SAHİN, BERKSOY
Format Journal Article
LanguageEnglish
Published Greece D.A. Spandidos 01.07.2015
Spandidos Publications
Spandidos Publications UK Ltd
Subjects
Age
Angiogenesis
Cancer
Care and treatment
cumulative dose
Development and progression
Diabetes
Dosage and administration
Dose-response relationship
Gender
Hydroxyapatite
jaw
Jaw diseases
Males
Metastasis
Multiple myeloma
Nitrogen
Observations
Oncology
Osteonecrosis
Patients
Prostate
Risk factors
Signal transduction
Standard deviation
Zoledronic acid
jaw
risk factors
osteonecrosis
cumulative dose
zoledronic acid
Online AccessGet full text

Cover

More Information
Summary:Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2015.3156